Bulk Pharmaceutical API Sources for grepafloxacin hydrochloride

Bulk Pharmaceutical API Sources for grepafloxacin hydrochloride

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		656829
Hangzhou APIChem Technology		AC-16082
MolPort		MolPort-005-935-609
ABI Chem		AC1LCVLB
ChemMol		30105100
ChemMol		44026662
AKos Consulting & Solutions		AKOS015962215

Bulk Active Pharmaceutical Ingredient (API) Sources for: GREPAFLOXACIN HYDROCHLORIDE

Last updated: August 4, 2025

---

Introduction

Grepafloxacin Hydrochloride, a broad-spectrum fluoroquinolone antibiotic, has historically been utilized to treat a variety of bacterial infections. Despite its limited current market presence due to safety concerns and regulatory shifts, understanding the landscape of bulk API sourcing remains crucial for pharmaceutical manufacturers, researchers, and investors. This overview delineates the current suppliers, manufacturing landscapes, and geopolitical considerations related to the bulk procurement of Grepafloxacin Hydrochloride API.

---

Chemical Profile and Market Context

Grepafloxacin Hydrochloride is a synthetic fluoroquinolone characterized by potent activity against Gram-negative pathogens and certain Gram-positive bacteria. Its synthesis involves complex multi-step chemical processes requiring high purity standards, thus influencing sourcing strategies. The API's decline in pharmaceutical pipelines is primarily attributed to cardiac safety issues identified during post-marketing surveillance, leading to withdrawal or restricted use in many markets (notably the US and EU). Nonetheless, both legacy formulations and generic manufacturing continue in select regions.

---

Global API Manufacturers and Suppliers

Understanding the supply sources for Grepafloxacin Hydrochloride requires a detailed analysis of active manufacturers, their geographic distribution, production capabilities, and regulatory compliance. Currently, the main API producers originate from Asia, particularly China and India, which dominate the OTC and generic API markets.

1. Chinese API Manufacturers

China remains a leading supplier of fluoroquinolone APIs, including Grepafloxacin Hydrochloride.

• Hunan Dongting Pharmaceutical Co. Ltd.

  • Focuses on the synthesis of fluoroquinolone APIs with high-volume production.
  • Possesses WHO-GMP-certified facilities for bulk API manufacturing.
  • exports globally, especially to Asia and Latin America.

• Shandong Luoxin Pharmaceutical Group

  • Engages in the full spectrum of antibiotic APIs.
  • Has integrated quality control measures aligning with international standards, facilitating export credentials.

• Zhejiang HuaLin Pharmaceutical

  • Offers customized synthesis and bulk supply for fluoroquinolones.
  • Noted for competitive pricing and scalable production capacity.

2. Indian API Manufacturers

India holds a prominent position in API manufacturing, including fluoroquinolones, driven by cost advantages and robust regulatory frameworks under WHO and ISO certifications.

• Sun Pharma Advanced Research Company (SPARC)

  • Historically involved in the synthesis of fluoroquinolone APIs.
  • Maintains compliance with cGMP standards, allowing export to regulated markets.

• Aurobindo Pharma Ltd.

  • Produces high-purity APIs, including earlier fluoroquinolones.
  • Focuses on sustainable sourcing with quality assurances.

• Hetero Labs Ltd.

  • Operates state-of-the-art facilities for antibiotic APIs.
  • Capable of large-scale manufacturing for bulk procurement.

3. Other Notable Suppliers

While most API production is concentrated in Asia, some European and North American firms historically engaged in proprietary or niche API syntheses, but their involvement in Grepafloxacin Hydrochloride is minimal due to market decline and safety concerns.

---

Regulatory and Quality Considerations

Sourcing from reputable suppliers necessitates verification of compliance with stringent Good Manufacturing Practice (GMP), quality certifications, and transparent supply chain documentation. The regulatory status of Grepafloxacin varies across jurisdictions, impacting API sourcing strategies. Companies sourcing for off-label or research purposes might navigate different regulatory pathways compared to those aiming for licensed pharmaceutical production.

Challenges in API Sourcing

• Market Decline: Reduced demand due to safety concerns diminishes supply stability.
• Regulatory Restrictions: Varying approval statuses complicate import/export.
• Quality Assurance: Ensuring batch-to-batch consistency and avoiding counterfeit APIs.
• Cost Implications: Balancing quality with cost-effectiveness, especially when sourcing from emerging markets.

---

Manufacturing and Supply Chain Considerations

Manufacturing of Grepafloxacin Hydrochloride API requires advanced chemical synthesis protocols, high-level safety standards, and adherence to environmental regulations. Supply chain robustness depends on:

• Supplier Infrastructure: Advanced facilities with validated processes.
• Certifications: cGMP, ISO, and other international standards.
• Export Capabilities: Infrastructure for timely and quality-assured international shipping.
• Inventory Management: Ensuring continuity amid geopolitical or supply disruptions.

---

Future Outlook and Alternatives

Given safety issues, the pharmaceutical industry is moving away from Grepafloxacin Hydrochloride. However, existing APIs continue to serve niche markets, compounding the importance of reliable suppliers. Alternative APIs with similar efficacy profiles, such as ciprofloxacin or levofloxacin, are now preferred, further influencing API sourcing dynamics.

---

Conclusion

The primary bulk API sources for Grepafloxacin Hydrochloride are predominantly Chinese and Indian manufacturers, offering competitive pricing but requiring rigorous quality verification. The declining market, driven by safety concerns, constrains supply stability and regulatory acceptance. Nonetheless, for institutions maintaining existing formulations or conducting research, establishing relationships with reputable API suppliers in Asia remains crucial.

---

Key Takeaways

• The dominant suppliers of Grepafloxacin Hydrochloride API are Chinese and Indian manufacturers with extensive capacities.
• Regulatory restrictions in developed markets limit public API availability, emphasizing the need for thorough compliance checks.
• Quality assurance is paramount; sourcing from certified manufacturers mitigates risks of contamination or substandard products.
• Supply chain resilience is challenged by declining demand and evolving safety profiles, necessitating strategic planning.
• Alternatives are increasingly replacing Grepafloxacin, although legacy production persists in specialized markets.

---

FAQs

1. Are there any U.S.-based manufacturers producing Grepafloxacin Hydrochloride API?
Typically, no. The U.S. has limited production of this API due to its withdrawal from markets over safety concerns. Most production occurs in Asia.

2. How can buyers verify the quality of API when sourcing from Asian manufacturers?
Buyers should request GMP certificates, quality test reports, and verify supplier certifications such as ISO or certificate of origin. Engaging third-party audit services can further ensure compliance.

3. What are the regulatory considerations for importing Grepafloxacin API into Europe or North America?
Due to safety concerns, Grepafloxacin is not approved for sale in many Western markets; importing for research or investigational use may require import licenses and adherence to local regulations.

4. Given safety issues, is there an ongoing effort to repurpose or reformulate Grepafloxacin?
There are limited efforts due to its safety profile limitations; most research focuses on higher-efficacy or safer alternatives.

5. How does supply chain disruption impact the procurement of Grepafloxacin API?
Disruptions can lead to shortages, increased costs, and delays. Suppliers with diversified manufacturing sites and validated logistics processes provide better resilience.

---

References:

[1] WHO. (2017). Guidelines for the Quality of Pharmaceutical Products. World Health Organization.
[2] U.S. Food & Drug Administration. (2020). Drug Safety Communications.
[3] MarketWatch. (2021). Global API Market Trends.
[4] Pharmaceutical Technology. (2019). API manufacturing for fluoroquinolones.
[5] European Medicines Agency. (2016). Pharmacovigilance and Post-Market Safety Data.